Marco Viganò1, Enrico Ragni1, Berardo Di Matteo2,3, Francesco Manlio Gambaro4,5, Carlotta Perucca Orfei1, Giuseppina Spinelli4,5, Alessandra Colombini1, Laura de Girolamo1, Elizaveta Kon5,6. 1. Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi 4, 21061, Milano, Italy. 2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy. berardo.dimatteo@gmail.com. 3. IRCCS Humanitas Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy. berardo.dimatteo@gmail.com. 4. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy. 5. IRCCS Humanitas Research Center, Via Manzoni 56, 20089, Rozzano, MI, Italy. 6. Department of Traumatology, Orthopaedics and Disaster Surgery, Sechenov First Moscow State Medical University (Sechenov University), 6-1 Bolshaya Pirogovskaya st, 119991, Moscow, Russia.
Abstract
PURPOSE: The aims of the present study were: (1) to characterize the bone-marrow aspirate (BMA) obtained with a centrifuge-free process, employing a dedicated aspiration device; (2) to test the in vitro efficacy of BMA in a model of cartilage inflammation; and (3) to report the preliminary clinical results in a small cohort of patients affected by knee OA. METHODS: Ten patients (4 M, 6 W; mean age: 51.9 ± 9.2 yy) affected by mild to moderate unicompartmental knee OA (KL grade 2-3) were treated by intra-articular and subchondral injections of BMA obtained by a centrifuge-free process. To evaluate the effectiveness of the device in harvesting mesenchymal stem cells (MSCs), samples of the obtained BMA were tested by flow cytometry before and after subculture; BMA ability to counteract inflammation was also tested in an in vitro model of cartilage cell inflammation, evaluating the expression of MMP1, MMP3, TGFβ and TIMP-1 by real-time PCR. Patients were also evaluated up to two years' follow-up by using: VAS for pain, IKDC-subjective and KOOS scores. RESULTS: The laboratory analysis showed that BMSCs accounted for 0.011% of BMA cells, similar to what had been expected in native bone marrow. The paracrine activity of BMA was able to reduce in vitro the catabolic response of human chondrocyte, as shown by the decrease in metalloproteases concentration and increase in anti-inflammatory mediators. Moreover, the clinical evaluation showed significant improvements in all scores adopted, with stable results up to two years. CONCLUSION: The present data showed the effectiveness of the study device to harvest pure bone marrow with minimal peripheral blood contamination. The relevant content of MSCs resulted in the ability to counteract the catabolic cascade through a paracrine action. The clinical outcomes in patients affected by unicompartmental knee OA were encouraging in terms of pain reduction and functional improvement up to mid-term evaluation.
PURPOSE: The aims of the present study were: (1) to characterize the bone-marrow aspirate (BMA) obtained with a centrifuge-free process, employing a dedicated aspiration device; (2) to test the in vitro efficacy of BMA in a model of cartilage inflammation; and (3) to report the preliminary clinical results in a small cohort of patients affected by knee OA. METHODS: Ten patients (4 M, 6 W; mean age: 51.9 ± 9.2 yy) affected by mild to moderate unicompartmental knee OA (KL grade 2-3) were treated by intra-articular and subchondral injections of BMA obtained by a centrifuge-free process. To evaluate the effectiveness of the device in harvesting mesenchymal stem cells (MSCs), samples of the obtained BMA were tested by flow cytometry before and after subculture; BMA ability to counteract inflammation was also tested in an in vitro model of cartilage cell inflammation, evaluating the expression of MMP1, MMP3, TGFβ and TIMP-1 by real-time PCR. Patients were also evaluated up to two years' follow-up by using: VAS for pain, IKDC-subjective and KOOS scores. RESULTS: The laboratory analysis showed that BMSCs accounted for 0.011% of BMA cells, similar to what had been expected in native bone marrow. The paracrine activity of BMA was able to reduce in vitro the catabolic response of human chondrocyte, as shown by the decrease in metalloproteases concentration and increase in anti-inflammatory mediators. Moreover, the clinical evaluation showed significant improvements in all scores adopted, with stable results up to two years. CONCLUSION: The present data showed the effectiveness of the study device to harvest pure bone marrow with minimal peripheral blood contamination. The relevant content of MSCs resulted in the ability to counteract the catabolic cascade through a paracrine action. The clinical outcomes in patients affected by unicompartmental knee OA were encouraging in terms of pain reduction and functional improvement up to mid-term evaluation.
Authors: P C Kreuz; M R Steinwachs; C Erggelet; S J Krause; G Konrad; M Uhl; N Südkamp Journal: Osteoarthritis Cartilage Date: 2006-07-11 Impact factor: 6.576
Authors: Mohamed A Imam; James Holton; Lukas Ernstbrunner; Wojciech Pepke; Florian Grubhofer; Ali Narvani; Martyn Snow Journal: Int Orthop Date: 2017-08-13 Impact factor: 3.075
Authors: Keng Lin Wong; Kevin Boon Leng Lee; Bee Choo Tai; Ping Law; Eng Hin Lee; James H P Hui Journal: Arthroscopy Date: 2013-12 Impact factor: 4.772
Authors: Payal Ganguly; Jehan J El-Jawhari; Peter V Giannoudis; Agata N Burska; Frederique Ponchel; Elena A Jones Journal: Cell Transplant Date: 2017-09 Impact factor: 4.064
Authors: Richard Schäfer; Malcolm R DeBaun; Erika Fleck; Christopher J Centeno; Daniela Kraft; Johannes Leibacher; Karen Bieback; Erhard Seifried; Jason L Dragoo Journal: J Transl Med Date: 2019-04-08 Impact factor: 5.531